Kenji Arakawa

T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes.

Akira Oku, Kiichiro Ueta, Kenji Arakawa et al. · Diabetes · 1999 · 251 citations

Novel Approach, Na+-glucose Cotransporters, Insulin Signaling +23

Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

Yin Liang, Kenji Arakawa, Kiichiro Ueta et al. · PLoS ONE · 2012 · 242 citations · Full text

Improved diabetic syndrome in C57BL/KsJ‐db/db mice by oral administration of the Na⁺‐glucose cotransporter inhibitor T‐1095

Kenji Arakawa, Tomomi Ishihara, Akira Oku et al. · British Journal of Pharmacology · 2001 · 161 citations · Full text

C57bl/ksj‐db/db Mice, Glucose Excretion, Diabetic Syndrome +21

Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus

Hiroyuki Tanaka, Kazuhiko Takano, Hiroaki Iijima et al. · Advances in Therapy · 2016 · 132 citations · Full text

Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice

Farhana Naznin, Hideyuki Sakoda, Tadashi Okada et al. · European Journal of Pharmacology · 2016 · 116 citations

Obesity, Metabolic Syndrome, Inflammation +12